share_log

Checkpoint Therapeutics FY23 EPS $(3.17) Vs $(7.09) YoY; As Of December 31, 2023, Checkpoint's Cash And Cash Equivalents Totaled $4.9M

Checkpoint Therapeutics FY23 EPS $(3.17) Vs $(7.09) YoY; As Of December 31, 2023, Checkpoint's Cash And Cash Equivalents Totaled $4.9M

Checkpoint Therapeutics23財年每股收益爲3.17美元,同比增長7.09美元;截至2023年12月31日,Checkpoint的現金和現金等價物總額爲490萬美元
Benzinga ·  03/22 08:38

Financial Results:

財務業績:

  • Cash Position: As of December 31, 2023, Checkpoint's cash and cash equivalents totaled $4.9 million, compared to $12.1 million at December 31, 2022, a decrease of $7.2 million. This cash position is not reflective of the registered direct offering that closed in January 2024 for total gross proceeds of approximately $14.0 million.
  • R&D Expenses: Research and development expenses for the year ended December 31, 2023, were $43.6 million, compared to $49.8 million for the year ended December 31, 2022, a decrease of $6.2 million. Research and development expenses for the year ended December 31, 2023 included $4.6 million of non-cash stock expenses, compared to $2.8 million in non-cash stock expenses for the year ended December 31, 2022.
  • G&A Expenses: General and administrative expenses for both the years ended December 31, 2023 and December 31, 2022, were $8.7 million. General and administrative expenses for the year ended December 31, 2023 included $2.7 million of non-cash stock expenses, compared to $2.5 million in non-cash stock expenses for the year ended December 31, 2022.
    • Net Loss: Net loss attributable to common stockholders for the year ended December 31, 2023, was $51.8 million, or $3.17 per share, compared to a net loss of $62.6 million, or $7.09 per share, for the year ended December 31, 2022.
  • 現金狀況:截至2023年12月31日,Checkpoint的現金及現金等價物總額爲490萬美元,而截至2022年12月31日爲1,210萬美元,減少了720萬美元。該現金狀況並未反映2024年1月結束的註冊直接發行,總收益約爲1,400萬美元。
  • 研發費用:截至2023年12月31日止年度的研發費用爲4,360萬美元,而截至2022年12月31日的年度爲4,980萬美元,減少了620萬美元。截至2023年12月31日止年度的研發費用包括460萬美元的非現金股票支出,而截至2022年12月31日止年度的非現金股票支出爲280萬美元。
  • 併購費用:截至2023年12月31日和2022年12月31日止年度的一般和管理費用均爲870萬美元。截至2023年12月31日止年度的一般和管理費用包括270萬美元的非現金股票支出,而截至2022年12月31日止年度的非現金股票支出爲250萬美元。
    • 淨虧損:截至2023年12月31日止年度,歸屬於普通股股東的淨虧損爲5,180萬美元,合每股虧損3.17美元,而截至2022年12月31日止年度的淨虧損爲6,260萬美元,合每股虧損7.09美元。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論